ATNM Quote, Financials, Valuation and Earnings

Karyopharm Therapeutics, Inc. has a net margin of -5701.11% compared to Actinium Pharmaceuticals, Inc.'s net margin of -75.21%. Actinium Pharmaceuticals, Inc.'s return on equity of -133.63% beat Karyopharm Therapeutics, Inc.'s return on equity of --.

Actinium Pharmaceuticals, Inc. has a consensus price target of $5.00, signalling upside risk potential of 244.83%. On the other hand Karyopharm Therapeutics, Inc. has an analysts' consensus of $14.67 which suggests that it could grow by 168.62%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Karyopharm Therapeutics, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Karyopharm Therapeutics, Inc..

Actinium Pharmaceuticals, Inc. has a beta of -0.367, which suggesting that the stock is 136.662% less volatile than S&P 500. In comparison Karyopharm Therapeutics, Inc. has a beta of 0.228, suggesting its less volatile than the S&P 500 by 77.201%.

Actinium Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Karyopharm Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Karyopharm Therapeutics, Inc. pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals, Inc. quarterly revenues are $90K, which are smaller than Karyopharm Therapeutics, Inc. quarterly revenues of $44M. Actinium Pharmaceuticals, Inc.'s net income of -$5.1M is higher than Karyopharm Therapeutics, Inc.'s net income of -$33.1M. Notably, Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Karyopharm Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals, Inc. is 502.60x versus 0.33x for Karyopharm Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -5701.11% compared to Actinium Pharmaceuticals, Inc.'s net margin of -255.85%. Actinium Pharmaceuticals, Inc.'s return on equity of -133.63% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Actinium Pharmaceuticals, Inc. has a consensus price target of $5.00, signalling upside risk potential of 244.83%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Actinium Pharmaceuticals, Inc. has a beta of -0.367, which suggesting that the stock is 136.662% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Actinium Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Actinium Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals, Inc. quarterly revenues are $90K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Actinium Pharmaceuticals, Inc.'s net income of -$5.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals, Inc. is 502.60x versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -5701.11% compared to Actinium Pharmaceuticals, Inc.'s net margin of --. Actinium Pharmaceuticals, Inc.'s return on equity of -133.63% beat Palatin Technologies's return on equity of --.

Actinium Pharmaceuticals, Inc. has a consensus price target of $5.00, signalling upside risk potential of 244.83%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Actinium Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Actinium Pharmaceuticals, Inc..

Actinium Pharmaceuticals, Inc. has a beta of -0.367, which suggesting that the stock is 136.662% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Actinium Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals, Inc. quarterly revenues are $90K, which are larger than Palatin Technologies quarterly revenues of --. Actinium Pharmaceuticals, Inc.'s net income of -$5.1M is higher than Palatin Technologies's net income of --. Notably, Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals, Inc. is 502.60x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Arcus Biosciences, Inc. has a net margin of -5701.11% compared to Actinium Pharmaceuticals, Inc.'s net margin of -519.23%. Actinium Pharmaceuticals, Inc.'s return on equity of -133.63% beat Arcus Biosciences, Inc.'s return on equity of -66.45%.

Actinium Pharmaceuticals, Inc. has a consensus price target of $5.00, signalling upside risk potential of 244.83%. On the other hand Arcus Biosciences, Inc. has an analysts' consensus of $33.22 which suggests that it could grow by 29.62%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Arcus Biosciences, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Arcus Biosciences, Inc..

Actinium Pharmaceuticals, Inc. has a beta of -0.367, which suggesting that the stock is 136.662% less volatile than S&P 500. In comparison Arcus Biosciences, Inc. has a beta of 0.747, suggesting its less volatile than the S&P 500 by 25.335%.

Actinium Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcus Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actinium Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Arcus Biosciences, Inc. pays out -- of its earnings as a dividend.

Actinium Pharmaceuticals, Inc. quarterly revenues are $90K, which are smaller than Arcus Biosciences, Inc. quarterly revenues of $26M. Actinium Pharmaceuticals, Inc.'s net income of -$5.1M is higher than Arcus Biosciences, Inc.'s net income of -$135M. Notably, Actinium Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Arcus Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actinium Pharmaceuticals, Inc. is 502.60x versus 10.76x for Arcus Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.